Immediate Impact
19 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy
2025 Standout
Works of Thomas Cummin being referenced
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
2020
Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
2020
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Thomas Cummin | 16 | 32 | 18 | 6 | 46 | |
| Alfred Leipold | 9 | 15 | 18 | 8 | 46 | |
| Srivalli Gopaluni | 14 | 11 | 9 | 8 | 34 | |
| Amy Saur | 17 | 35 | 16 | 5 | 60 | |
| Massimo Di Gioia | 10 | 30 | 17 | 6 | 49 | |
| Katya Ahr | 28 | 18 | 20 | 4 | 44 | |
| Valentina Bonuomo | 13 | 10 | 22 | 7 | 48 | |
| Hui San Chin | 5 | 49 | 7 | 6 | 61 | |
| Carla Araujo | 11 | 27 | 35 | 8 | 57 | |
| Alexander Waldrop | 14 | 24 | 32 | 5 | 69 | |
| Fabrizio Ciambelli | 4 | 25 | 12 | 7 | 58 |
All Works
Loading papers...